文献速递男科与性医学

性激素结合球蛋白在性腺功能减退症及不育男性中的效用

The Utility of Sex Hormone-Binding Globulin in Hypogonadism and Infertile Males.
PubMed 文献 · J Urol · 2017-01-10

该研究回顾性分析了2012至2014年生育门诊168例男性的病历,以计算的生物可利用睾酮为标准评估总睾酮诊断性腺功能减退的准确性,并用多变量分析评估性激素结合球蛋白作为不育独立预测因子的价值。结果显示,在总睾酮基础上加测性激素结合球蛋白有助于更准确诊断,并提示性激素结合球蛋白对精液参数下降的临床意义与促卵泡激素相似,作者认为这值得进一步研究。

要点

  • 单用总睾酮诊断性腺功能减退的敏感性为81%、特异性为83%。
  • 总睾酮大于300 ng/dl的90例中,20%生物可利用睾酮低于156 ng/dl。
  • 性激素结合球蛋白可独立预测精子浓度下降(p=0.0027)和活力下降(p=0.0447)。

核心结论

  • 在总睾酮血清检测基础上加测性激素结合球蛋白,有助于利用游离睾酮和计算的生物可利用睾酮更准确地进行诊断,并对精液参数下降显示出与促卵泡激素相似程度的临床意义。
  • 作者认为这值得进一步研究性激素结合球蛋白在男性不育中的作用。

研究设计与样本

  • 回顾性研究,回顾了2012年至2014年在生育门诊就诊的168例男性的病历。
  • 以计算的生物可利用睾酮为参考值,评估总睾酮在性腺功能减退生化诊断中的准确性,并用多变量分析评估性激素结合球蛋白作为不育独立预测因子的价值。

主要发现

  • 以计算的生物可利用睾酮低于156 ng/dl为确定性生化性腺功能减退标准,单用总睾酮诊断的敏感性为81%、特异性为83%、阳性预测值为81%、阴性预测值为82%。
  • 总睾酮大于300 ng/dl的90例男性中,20%生物可利用睾酮低于156 ng/dl,52%生物可利用睾酮处于低于210 ng/dl的边缘性低值,仅48%按计算的生物可利用睾酮可视为生化正常。
  • 总睾酮低于300 ng/dl的80例患者中,19%游离睾酮大于6.5 ng/dl,因此可视为性腺功能正常。
  • 性激素结合球蛋白独立预测精子浓度下降(p=0.0027)和活力下降(p=0.0447),其程度与促卵泡激素相似。
  • 排除无精子症男性后,经典性腺功能减退男性(第1组,总睾酮低于300 ng/dl)与被漏诊但存在性腺功能减退的男性(第2组,计算的生物可利用睾酮低于210 ng/dl)之间仅性激素结合球蛋白水平存在显著差异(p=0.0001);在更严格的 cut-off 值计算的生物可利用睾酮低于156 ng/dl时,第1组与第2组精子活力存在显著差异(p=0.014)。

临床怎么用

  • 作者认为,在总睾酮血清检测基础上加测性激素结合球蛋白有助于更准确地诊断性腺功能减退。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: We sought to determine the role of sex hormone-binding globulin in patients with male infertility. MATERIALS AND METHODS: We retrospectively reviewed the records of 168 males seen at a fertility clinic from 2012 to 2014 to investigate the accuracy of total testosterone in the biochemical diagnosis of hypogonadism using calculated bioavailable testosterone as the reference value. We used multivariable analysis to assess sex hormone-binding globulin as an independent predictor of infertility. RESULTS: Computations using calculated bioavailable testosterone as a standard in the measurement of definitive biochemical hypogonadism (less than 156 ng/dl) revealed 81% sensitivity, 83% specificity, 81% positive predictive value and 82% negative predictive value for diagnosing hypogonadism with total testosterone alone. Of the 90 men with total testosterone greater than 300 ng/dl, 20% had low bioavailable testosterone less than 156 ng/dl, 52% had borderline low bioavailable testosterone less than 210 ng/dl and only 48% could be considered biochemically eugonadal according to calculated bioavailable testosterone. Of the 80 patients with total testosterone less than 300 ng/dl, 19% had free testosterone levels greater than 6.5 ng/dl and, thus, could be considered to be eugonadal. By a magnitude similar to that of follicle-stimulating hormone, sex hormone-binding globulin independently predicted decreased sperm concentration (p = 0.0027) and motility (p = 0.0447). After excluding men with azoospermia, only sex hormone-binding globulin levels differed significantly in classically hypogonadal men (group 1-total testosterone less than 300 ng/dl) and those missed but hypogonadal (group 2-calculated bioavailable testosterone less than 210 ng/dl) (p = 0.0001). At a more stringent cutoff of calculated bioavailable testosterone less than 156 ng/dl, sperm motility was significantly different for groups 1 and 2 (p = 0.014). CONCLUSIONS: Adding sex hormone-binding globulin to total testosterone serum testing facilitates more accurate diagnosis with free testosterone and calculated bioavailable testosterone, and clinical implications of decreased semen parameters to a magnitude similar to that of follicle-stimulating hormone. This warrants further study of the role of sex hormone-binding globulin in male infertility.

来源:J Urol,查看原文。版权归原作者所有。

引用

  1. Ring J, Welliver C, Parenteau M, et al. The Utility of Sex Hormone-Binding Globulin in Hypogonadism and Infertile Males. J Urol. 2017. PMID: 28087298. doi:10.1016/j.juro.2017.01.018

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。